Scott Robert Solomon MD

Myeloproliferative Disorder Hematology-Oncology

Physician

5670 Peachtree Dunwoody RdSte 1000Atlanta, GA 30342
Phone+1 404-255-1930
Fax+1 404-459-8510

Dr. Solomon is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Solomon's full profile Already have an account?

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1998 - 2001
University of California (San Francisco)Residency, Internal Medicine, 1995 - 1998
University of Maryland School of MedicineClass of 1995

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 1997 - Present
GA State Medical License 2005 - 2027
MD State Medical License 2000 - 2005
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) Start of enrollment: 2004 Aug 01
Terminated
Phase 2, Phase 3
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer Start of enrollment: 2008 Oct 01
Completed
Phase 2
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer Start of enrollment: 2005 May 01
Terminated
Phase 2

Publications & Presentations

PubMed

Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.
William G Wierda, Kathleen A Dorritie, Jordan Gauthier, Rajneesh Nath, Thomas J Kipps
Blood. 2026-07-28
Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.
Lara Stepan, Sahar Ansari, Jeremy S Abramson, Abood Okal, Justine Dell'Aringa
Journal of Clinical Oncology. 2026-07-01
Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCL.
Jeremy S Abramson, Tanya Siddiqi, Leo I Gordon, Matthew A Lunning, Michael Wang
Blood. 2026-06-03

Abstracts/Posters

Graft Versus Host Disease (GVHD) after HLA-Mismatched Haploidentical Transplantation with Post-Transplant Cyclophosphamide Compared to Matched Unrelated Donor: Inciden...
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
SEL120 _ a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinica...
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Improved Survival in Patients Who Undergo Relapse of Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Trans...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019